The antibacterial medicine sales in Canada exhibit a declining trend from 2024 to 2028, starting at $299.4 million in 2024 and anticipated to decrease to $221.3 million in 2028. This reflects a compound annual growth rate (CAGR) of decrease during this period. From 2023, sales dropped significantly, indicating a year-on-year negative trend that warrants analysis for potential causes.

Future trends to watch for include:

Increased regulation and stewardship in antibacterial prescription.
Potential market shifts towards non-antibiotic therapies.
Technological advancements in diagnostic alternatives reducing antibacterial use.
Public health initiatives to curb unnecessary antibiotic consumption.